Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 3/20 | 0.55 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022317 | 0.86 | HDAC1 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3026652 | 0.86 | HDAC1 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3022315 | 0.86 | HDAC1 (0.49) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL28934086 | 0.81 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3869968 | 0.81 | POLB (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4655916 | 0.81 | SMN1; SMN2 (0.55) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL9944384 | 0.81 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30574349 | 0.79 | MAPK1 (0.67) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL64763 | 0.79 | MAPK1 (0.67) | HDAC1HDAC6CA12CA1CA2 | |
| SCHEMBL3590924 | 0.79 | CA12 (0.51) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611857-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-114195759-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海零诺生物科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115611857-A | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| CN-114195759-A | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 广州天然科技有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-115611857-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-114195759-B | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海零诺生物科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-115611857-A | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 上海伍夫科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-114989135-A | Organic acid salt of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine and preparation method thereof | 广州天然科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114195759-A | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine | 广州天然科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-2941426-B1 | SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9266878-B2 | Phosphatidylinositol 3-kinase inhibitors | GILEAD CALISTOGA LLC (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2015-08-06 | — | — | US | disclosed |
| US-8580790-B2 | (Heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20120245149-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245149-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120148955-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| WO-2011080444-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALCANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS P75 INHIBITORS | SANOFI-AVENTIS (FR) | 2011-07-07 | — | — | WO | disclosed |
| CN-101857567-A | Preparation method of high-purity 2,5-dipicolinic acid | ZHEJIANG DINGLONG CHEMICALS CO LTD | 2010-10-13 | — | — | CN | disclosed |
| EP-0128279-B1 | PROCESS FOR THE PREPARATION OF 6-METHYL-NICOTINIC-ACID ESTERS | LONZA AG (CH) | 1989-01-25 | — | — | EP | disclosed |
| US-4579953-A | OXIDIZING 2-METHYL-5-ETHYLPYRIDINE, ESTERIFYING WITH AN ALCOHOL | LONZA LTD. (CH) | 1986-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218154-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3CA, PIK3R5, PIK3R4 | HDAC1 593/4885HDAC6 682/4885CA12 4776/4885 |
| US-20120148955-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, AND NEW COMPOUND | C1R, SLC11A2, RER1 | HDAC1 2069/4885HDAC6 3364/4885CA12 1296/4885 |
| US-20120245149-A1 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS | NTRK2, NTRK3, NGF | HDAC1 96/4885HDAC6 584/4885CA12 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.